Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neurology

What Is the POTS Trifecta? hEDS, MCAS, & POTS Explained

At a Glance

The POTS trifecta is the common overlap of Postural Orthostatic Tachycardia Syndrome (POTS), hypermobile Ehlers-Danlos Syndrome (hEDS), and Mast Cell Activation Syndrome (MCAS). These conditions interact through a cycle of stretchy blood vessels, immune flare-ups, and a rapidly racing heart.

The “POTS trifecta” is a term frequently used in the medical and patient communities to describe the common co-occurrence of three conditions: Postural Orthostatic Tachycardia Syndrome (POTS), hypermobile Ehlers-Danlos Syndrome (hEDS), and Mast Cell Activation Syndrome (MCAS) [1][2]. While the “trifecta” is not a single official diagnosis, it represents a widely recognized clinical pattern [1].

If you have been diagnosed with POTS and feel like your symptoms go far beyond your heart rate—perhaps including joint instability, chronic pain, severe allergies, or flushing—you may be experiencing this triad [3][4]. Symptoms of these conditions often emerge progressively over a patient’s lifetime, sometimes accelerating after a major stressor or viral illness [5]. While they are separate conditions—affecting the autonomic nervous system, connective tissue, and immune system—they overlap and worsen one another’s symptoms [1][6].

Understanding this overlap is essential because treating just the fast heart rate of POTS is often ineffective if the underlying structural and immune issues are ignored [3][7].

hEDS and POTS: The Connective Tissue Link

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a genetic disorder that results in faulty collagen, the “glue” that holds your body’s connective tissues together [2][8]. While hEDS is famous for causing flexible, unstable joints, connective tissue is also a major component of your blood vessel walls.

When you have hEDS, your blood vessels (particularly your veins) can be unusually stretchy or lax [9][10]. Normally, when you stand up, your blood vessels constrict to push blood back up to your heart and brain against gravity. In hEDS, this increased venous compliance (stretchiness) means the veins stretch out and allow excessive amounts of blood to pool in your lower body [11][10]. To compensate for this massive drop in blood return, your brain sends a panic signal to your heart, telling it to beat much faster (tachycardia) to keep your blood pressure stable [10]. This is how the structural laxity of hEDS directly triggers the primary symptom of POTS [12][10].

Diagnosis of hEDS typically involves a clinical exam by a geneticist or rheumatologist, utilizing tools like the Beighton score to assess joint hypermobility along with a detailed family and medical history [8].

MCAS and POTS: The Immune Link

Mast Cell Activation Syndrome (MCAS) is an immune condition where mast cells—the cells responsible for allergic reactions—are overly sensitive and inappropriately release inflammatory chemicals, or mediators, in response to ordinary triggers like certain foods, temperature changes, or stress [3][6].

The most well-known mediator is histamine, but mast cells also release prostaglandins and leukotrienes [13][14]. A primary function of histamine is vasodilation, meaning it forces blood vessels to widen and relax [13]. If you have MCAS and your mast cells suddenly dump histamine into your bloodstream, your blood vessels widen rapidly. When combined with the already stretchy veins of hEDS, this causes a dramatic worsening of blood pooling [15][3].

To fight this sudden, severe blood pooling, the autonomic nervous system goes into overdrive. It dumps massive amounts of adrenaline and norepinephrine into your system to force the heart to pump harder and the vessels to constrict [3][15]. This is why MCAS flares often cause severe tachycardia, anxiety, and heart palpitations, frequently driving the “hyperadrenergic” (high-adrenaline) subtype of POTS [3][15].

Evaluation for MCAS is usually managed by an allergist or immunologist. It often involves specialized blood and 24-hour urine tests to check for elevated mast cell mediators (like tryptase or histamine metabolites), ideally captured during a symptom flare [16][17].

Is There a Unified Cause?

Because these three conditions appear together so frequently, researchers have hypothesized they might share a single genetic root cause [1]. Scientists are investigating several leads:

  • Hereditary Alpha-Tryptasemia (HaT): A clinically testable genetic trait causing elevated basal serum tryptase, which has been linked to both autonomic and connective tissue symptoms in some patients [18][19].
  • The RCCX Genetic Module: A complex genetic region where frequent mutations occur. While it is a popular theory in some communities, this connection remains highly speculative and lacks robust mainstream clinical validation [20][21].

Currently, large reviews have not proven a singular causal link [18][22]. The trifecta is best understood as a vicious cycle of overlapping conditions: structural laxity causes blood pooling, immune reactions worsen that pooling, and the nervous system burns itself out trying to compensate [1][3].

Coordinating Comprehensive Treatment

If you suspect you have the POTS trifecta, standard POTS treatments (like drinking more water and increasing salt) may not be enough [7][3]. Effectively managing your symptoms often requires building a multidisciplinary care team—such as a dysautonomia specialist (neurologist or cardiologist), a geneticist or rheumatologist, and an immunologist [3].

Together, your team can use a multi-pronged approach to break the cycle:

  • Targeting the laxity (hEDS): Using firm, medical-grade compression garments (waist-high) to manually squeeze the blood vessels and prevent pooling [10]. (Note: Wrestling into tight compression can be exhausting with unstable joints; assistive devices like donning gloves can help prevent joint strain).
  • Targeting the mediators (MCAS): Using mast cell-stabilizing therapies (like cromolyn) or non-sedating H1 and H2 antihistamines (like cetirizine, fexofenadine, or famotidine) to stop the vasodilation [23][24][25]. Always consult your physician before starting a daily antihistamine protocol, as finding the right combination requires medical supervision.
  • Targeting the nervous system (POTS): Utilizing heart rate-lowering medications or beta-blockers to manage the sympathetic nervous system overdrive [3][10].

By understanding how hEDS and MCAS mechanically contribute to your POTS, you can better advocate for treatments that target the specific triggers driving your symptoms [3][2].

Common questions in this guide

What is the POTS trifecta?
The POTS trifecta refers to the common co-occurrence of three conditions: Postural Orthostatic Tachycardia Syndrome (POTS), hypermobile Ehlers-Danlos Syndrome (hEDS), and Mast Cell Activation Syndrome (MCAS). While not a single official diagnosis, they frequently overlap and worsen each other.
How does hEDS cause or trigger POTS?
Hypermobile Ehlers-Danlos Syndrome causes overly stretchy connective tissues, including blood vessels. When you stand up, these lax veins allow blood to pool in your lower body, prompting your heart to beat excessively fast to compensate, which is the hallmark symptom of POTS.
Why do MCAS flares make my POTS worse?
During an MCAS flare, mast cells release inflammatory chemicals like histamine that cause blood vessels to widen. This sudden widening worsens blood pooling, triggering your nervous system to release massive amounts of adrenaline and causing severe tachycardia.
What kind of doctors should I see for the POTS trifecta?
Managing these overlapping conditions usually requires a team of specialists working together. This often includes a dysautonomia specialist (such as a neurologist or cardiologist) for POTS, a geneticist or rheumatologist for hEDS, and an immunologist or allergist for MCAS.
Is there a single genetic cause for POTS, hEDS, and MCAS?
While researchers are investigating genetic links like Hereditary Alpha-Tryptasemia (HaT), large studies have not yet proven a single genetic root cause for all three conditions. The trifecta is currently best understood as a vicious cycle of structural, immune, and nervous system issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my combination of symptoms, do you think I should be evaluated for hypermobility spectrum disorders or MCAS, and who would you recommend I see for those specific assessments?
  2. 2.Could we check standing vs. supine plasma catecholamines to determine if my POTS has a hyperadrenergic component driven by this trifecta?
  3. 3.Are there any specific 24-hour urine tests or baseline blood tests, like a serum tryptase level, we should run to screen for mast cell involvement?
  4. 4.How can we coordinate my treatment plan between a cardiologist, rheumatologist, and allergist so that medications for one condition don't worsen another?
  5. 5.What are your thoughts on screening for Hereditary Alpha-Tryptasemia (HaT) given my symptom profile?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are There FDA-Approved Medications for POTS?Does Blood Pressure Drop With POTS? POTS vs. OH ExplainedDoes POTS Go Away? Long-Term Prognosis & RecoveryHow Does Ivabradine Work for POTS? Uses & Side EffectsHow Much Salt Per Day for POTS? Daily Sodium GuidelinesHow to Exercise with POTS: The CHOP & Levine ProtocolsHow to Stop a POTS Flare-Up: Fast Rescue StrategiesHow Do You Use Pacing and Spoon Theory for POTS Fatigue?Side Effects of Midodrine & Fludrocortisone for POTSWhat Are the Different Subtypes of POTS? (Key Symptoms)What Causes Secondary POTS? Triggers & Conditions ExplainedWhat Is Coat Hanger Pain in POTS? Causes and ReliefWhat Is the Best Compression for POTS Relief?POTS Tilt Table Test: What to Expect & How to PrepareWhy Are POTS Symptoms Worse in the Morning?Why Do Hot Showers Trigger POTS Symptoms & Dizziness?Why Is POTS Frequently Misdiagnosed as Anxiety?Why Is Recumbent Exercise Best for POTS?How to Get POTS Accommodations at Work & School

References

References (25)
  1. 1

    Idiopathic osteoporosis, Ehlers-Danlos syndrome, postural orthostatic tachycardia syndrome, and mast cell activation disorder in a 27-year-old male patient: A unique case presentation.

    Rattray C

    Clinical case reports 2022; (10(5)):e05887 doi:10.1002/ccr3.5887.

    PMID: 35600027
  2. 2

    Comorbidities and neurosurgical interventions in a cohort with connective tissue disorders.

    Ruhoy IS, Bolognese PA, Rosenblum JS, et al.

    Frontiers in neurology 2024; (15()):1484504 doi:10.3389/fneur.2024.1484504.

    PMID: 39931100
  3. 3

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  4. 4

    Prevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndrome.

    Boris JR, Bernadzikowski T

    Autonomic neuroscience : basic & clinical 2021; (231()):102770 doi:10.1016/j.autneu.2020.102770.

    PMID: 33388686
  5. 5

    Cardiovascular effects of the post-COVID-19 condition.

    Goerlich E, Chung TH, Hong GH, et al.

    Nature cardiovascular research 2024; (3(2)):118-129 doi:10.1038/s44161-023-00414-8.

    PMID: 39196189
  6. 6

    Self-reported Demographics of 154 Hypermobile Ehlers-Danlos Syndrome Patients.

    Ploeg AN, Courseault J, Cheng WS

    American journal of physical medicine & rehabilitation 2025; (104(10)):927-932 doi:10.1097/PHM.0000000000002766.

    PMID: 40300043
  7. 7

    Pediatric postural orthostatic tachycardia syndrome: From mechanisms to individualized management.

    Xu W, Jin H, Liao Y, Du J

    Pediatric discovery.. 2024; (2(4)):e2509 doi:10.1002/pdi3.2509.

    PMID: 40626134
  8. 8

    An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis.

    Wu W, Ho V

    Frontiers in neurology 2024; (15()):1379646 doi:10.3389/fneur.2024.1379646.

    PMID: 39268060
  9. 9

    Exploring the Association Between Median Arcuate Ligament Syndrome and Hypermobile Ehlers-Danlos Syndrome: A Case Report.

    Sorenson KR, Buckway T, Hall B

    Cureus 2025; (17(8)):e90988 doi:10.7759/cureus.90988.

    PMID: 41018362
  10. 10

    Water Ingestion in Postural Orthostatic Tachycardia Syndrome: A Feasible Treatment Option?

    The Journal of innovations in cardiac rhythm management 2019; (10(2)):3545-3551 doi:10.19102/icrm.2019.100207.

    PMID: 32494413
  11. 11

    Central arterial stiffness, flow-mediated dilation, and venous function in postural orthostatic tachycardia syndrome.

    Pugh GE, Thomas KN, Fan JL, Fisher JP

    American journal of physiology. Heart and circulatory physiology 2026; (330(1)):H89-H99 doi:10.1152/ajpheart.00590.2025.

    PMID: 41297031
  12. 12

    Decreased Stroke Volume and Venous Return in School Children with Postural Tachycardia Syndrome.

    Jimbo S, Fujita Y, Ishii W, et al.

    The Tohoku journal of experimental medicine 2021; (253(3)):181-190 doi:10.1620/tjem.253.181.

    PMID: 33731495
  13. 13

    Mast cell degranulation and de novo histamine formation contribute to sustained postexercise vasodilation in humans.

    Romero SA, McCord JL, Ely MR, et al.

    Journal of applied physiology (Bethesda, Md. : 1985) 2017; (122(3)):603-610 doi:10.1152/japplphysiol.00633.2016.

    PMID: 27562843
  14. 14

    Acute/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndrome.

    Butterfield JH, Taylor A

    The journal of allergy and clinical immunology. Global 2025; (4(2)):100399 doi:10.1016/j.jacig.2024.100399.

    PMID: 39906893
  15. 15

    Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.

    Allen SJ, Chazot PL, Dixon CJ

    British journal of clinical pharmacology 2018; (84(7)):1611-1616 doi:10.1111/bcp.13578.

    PMID: 29667234
  16. 16

    Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.

    Butterfield JH

    The journal of allergy and clinical immunology. In practice 2022; (10(8)):1974-1984 doi:10.1016/j.jaip.2022.03.008.

    PMID: 35346887
  17. 17

    Restless legs syndrome is associated with mast cell activation syndrome.

    Weinstock LB, Walters AS, Brook JB, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2020; (16(3)):401-408 doi:10.5664/jcsm.8216.

    PMID: 31994488
  18. 18

    Appraisal of the evidence linking hereditary α-tryptasemia with mast cell disorders, hypermobility and dysautonomia.

    Lyons JJ

    Allergy and asthma proceedings 2025; (46(1)):4-10 doi:10.2500/aap.2025.46.240088.

    PMID: 39741374
  19. 19

    Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.

    Rüfer A, Müllner G, Fuchs O, et al.

    Swiss medical weekly 2025; (155()):3679 doi:10.57187/s.3679.

    PMID: 40450750
  20. 20

    Genes and Pseudogenes: Complexity of the RCCX Locus and Disease.

    Carrozza C, Foca L, De Paolis E, Concolino P

    Frontiers in endocrinology 2021; (12()):709758 doi:10.3389/fendo.2021.709758.

    PMID: 34394006
  21. 21

    Molecular basis and genetic testing strategies for diagnosing 21-hydroxylase deficiency, including CAH-X syndrome.

    Kim JH, Kim GH, Yoo HW, Choi JH

    Annals of pediatric endocrinology & metabolism 2023; (28(2)):77-86 doi:10.6065/apem.2346108.054.

    PMID: 37401054
  22. 22

    Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review.

    Farley M, Estrada-Mendizabal RJ, Gansert EA, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (135(1)):97-102 doi:10.1016/j.anai.2025.03.022.

    PMID: 40185471
  23. 23

    COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

    Malone RW, Tisdall P, Fremont-Smith P, et al.

    Frontiers in pharmacology 2021; (12()):633680 doi:10.3389/fphar.2021.633680.

    PMID: 33833683
  24. 24

    A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome.

    Christoforou ME, van Campen LC, Visser FC, et al.

    Cureus 2026; (18(1)):e102064 doi:10.7759/cureus.102064.

    PMID: 41728426
  25. 25

    Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis.

    Giannetti MP, Weller E, Bormans C, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (126(6)):655-660 doi:10.1016/j.anai.2021.01.016.

    PMID: 33465452

This page explains the clinical connection between POTS, hEDS, and MCAS for educational purposes only. It does not replace professional medical advice. Always consult your specialists to evaluate and manage your specific symptoms.

Get notified when new evidence is published on Postural Orthostatic Tachycardia Syndrome (POTS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.